SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark achieves positive results for anti-diarrhoea molecule

08 Feb 2011 Evaluate

Drug firm Glenmark Pharmaceuticals has achieved positive results in human trials for its new drug molecule Crofelemer, which is aimed at treating diarrhea in adults.Resolution of diarrhea was significantly higher in human subjects, who were given Crofelemer compared to those who were not in a multi-centre trial. Crofelemer will potentially be the first new chemical entity (NCE) to be launched by the organization.

Glenmark will accelerate the development of Crofelemer in the acute indications, including pediatric diarrhea where several million individuals are affected in the geographies that we operate in. Crofelemer is licensed to the company from US-based Napo Pharmaceuticals. In November 2010, Glenmark along with Napo and Salix Pharmaceuticals, had announced the successful completion of phase III trials with Crofelemer for the treatment of diarrhea in patients with HIV in the US.

Glenmark has the exclusive license to develop, commercialise and distribute Crofelemer in 140 emerging countries for indications related to HIV, use in acute diarrhea, including supply to NGOs for delivery within these countries. Glenmark and Salix have also entered into a commercial supply agreement for Crofelemer active pharmaceutical ingredient,crackcrack

Glenmark Pharma Share Price

2229.65 -18.25 (-0.81%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×